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Abstract
Background: Brachyspira hyodysenteriae is the primary cause of swine dysentery, characterized by bloody to
mucoid diarrhea due to mucohaemorhagic colitis in pigs and primarily affects pigs during the grow/finishing stage.
Control and prevention of B. hyodysenteriae consists of administration of antimicrobial drugs, besides management
and adapted feeding strategies. A worldwide re-emergence of the disease has recently been reported with an
increasing number of isolates demonstrating decreased susceptibility to several crucially important antimicrobials in
the control of swine dysentery. A novel non-antibiotic zinc chelate has been reported to demonstrate positive
effects on fecal quality and consistency, general clinical signs, average daily weight gain and B. hyodysenteriae
excretion during and after a 6-day oral treatment. The objective of the present study was to evaluate the zinc
chelate (Intra Dysovinol® 499 mg/ml (ID); Elanco) on naturally occurring swine dysentery due to B. hyodysenteriae
under field conditions in the Netherlands.
Results: Oral administration of zinc chelate resulted in improvement of general clinical signs from 3 days onwards
in the ID-treated group combined with a significantly better total fecal score at 14 days post-treatment. Overall,
average daily weight gain was better in the ID-treated group over the entire study period (0–14 days) and during
the 8 days following the end of ID-treatment. A significant reduction (4.48 vs. 0.63 log10 cfu/g feces; ID-treated vs.
control) in B. hyodysenteriae excretion was observed during the 6-day treatment period with a high percentage of
animals (58.3 vs. 12.3%; ID-treated vs. control) with no excretion of B. hyodysenteriae from their feces. No additional
antimicrobial treatment was needed in the ID-treated group, whereas 35% of the pigs in the control group were
treated with an antibiotic at least once. No mortality occurred in both groups. No adverse events were reported
during and following the ID-treatment.
Conclusions: Zinc chelate – administered as a Zn-Na2-EDTA complex – is a non-antibiotic treatment for swine
dysentery that reduces B. hyodysenteriae shedding with 4.48 log10 cfu/g feces within its 6-day treatment while
improving general clinical signs (90.0 vs. 73.6% animals with normal score) and total fecal score within 2–4 days
following administration in naturally infected pigs. The positive effects of ID treatment remain for at least 8 days
after cessation of oral ID therapy. Pigs remaining in a highly contaminated environment may be re-infected
following the end of ID treatment, however, this is not different to standard antimicrobial therapy. Therefore,
control of swine dysentery should combine an efficacious treatment with additional management practices to
reduce the environmental infection pressure in order to limit re-infection as much as possible. The ID treatment
resulted in a higher growth rate and improved general health, whereas no mortality was observed and no
additional therapeutic treatments were necessary in contrast to the control pigs.
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Background
Brachyspira hyodysenteriae (B. hyodysenteriae) – a β-
haemolytic Gram-negative oxygen-tolerant anaerobic
spirochete – is the primary cause of swine dysentery,
characterized by bloody to mucoid diarrhea due to
mucohaemorhagic colitis is pigs [1]. Swine dysentery pri-
marily affects pigs during the growth and finishing
period. Transmission of B. hyodysenteriae occurs
through the fecal-oral route and is associated with sev-
eral risk factors such as introduction of colonized ani-
mals (carriers), poor external (quarantine, rodents, wild
birds and other potential reservoirs) and internal biose-
curity measures (adequate cleaning and disinfection pro-
tocols, mixing of age groups) [2]. Clinical signs usually
start with loss of appetite and mild, yellow to grey-
coloured diarrhea, further progressing to watery diarrhea
with blood, mucus and pseudomembranes [3]. This re-
sults in economic damage due to growth losses, mortal-
ity, increased variation in pig weight and decreased feed
conversion at farm level.
Control and prevention of B. hyodysenteriae mainly
consists of administration of antimicrobial drugs, besides
management and adapted feeding strategies [4]. Cur-
rently, no commercial vaccines against B. hyodysenteriae
are available [1], although some experimental vaccines,
such as bacterins, subunit vaccines and live attenuated
strains have been evaluated [5]. Recently, B. hyodysenter-
iae has been reported as a worldwide re-emerging dis-
ease with an increasing number of isolates having
decreased susceptibility to several crucially important
antibiotics in the control of swine dysentery [5–15].
Overall, control and prevention of B. hyodysenteriae
seems to become more challenging, due to the limited
treatment options [2], the lack of effective preventive
feeding strategies and the increased awareness on reduc-
tion of antimicrobial use in animal production [16].
Consequently, research focused on non-antibiotic al-
ternatives to reduce bacterial infections in general and B.
hyodysenteriae infections in particular becomes more
prominent. Adapted feeding strategies, including a high
dietary concentration of inulin, have proven to reduce
the incidence of swine dysentery due to B. hyodysenter-
iae in grower pigs [17]. A citrus extract commercialized
as raw material and used as feed additive showed rele-
vant in vitro bacteriostatic and bactericidal activity
against B. hyodysenteriae at relatively low concentrations
of 32 and 128 ppm, respectively [18]. Among others zinc
has been evaluated as a potential intervention to control
B. hyodysenteriae. In vitro addition of either ZnSO4 or
CuSO4 to the growth medium of B. hyodysenteriae
caused complete inhibition of hemolytic activity in 3 cul-
ture cycles. Further research revealed that the inhibition
of hemolysin was specifically mediated by Zn2+ [19]. A
comparative study with ZnSO4, Zn-methionine and ZnO
only demonstrated a prophylactic effect of high concen-
trations of in-feed ZnO (2000 ppm or higher) against B.
hyodysenteriae in a mouse challenge model for swine
dysentery [20]. However, in 2017, the Committee for
Medicinal Products of Veterinary Use concluded that
the benefits of ZnO for the prevention of diarrhea in
pigs do not outweigh the environmental risks of the
product [21]. The recent withdrawal of the marketing
authorization of ZnO by the European Commission
limits the availability of effective alternatives to anti-
microbial drugs. Consequently, there is a continuing
need for new, effective, non-antibiotic innovations to
further improve animal health and welfare and to help
reducing economic losses due to B. hyodysenteriae infec-
tions in pigs.
Chelation of zinc with an organic molecule to form a
Zn-Na2-EDTA – instead of covalent binding of zinc to
inorganic oxygen – reduces its environmental impact
[22]. In addition, previous in vitro (unpublished data)
and in vivo studies [22] have demonstrated that the Zn-
Na2-EDTA chelated complex – in relatively low concen-
trations – is potentially able to reduce adverse effects
due to B. hyodysenteriae infections in pigs. An in vivo
feasibility study demonstrated a positive effect of the
zinc chelate to fecal quality and consistency, general
clinical signs and average daily weight gain (ADWG) in
B. hyodysenteriae-infected animals. Moreover, at the last
treatment day, B. hyodysenteriae was not detectable by
qPCR in most of the treated animals [22]. Based on
these promising in vitro and in vivo results, the goal of
the present study was to assess the efficacy of the zinc
chelate, formulated as the Veterinary Medicinal Product
Intra Dysovinol® 499 mg/ml (ID; Elanco, Greenfield, IN)
in the treatment of clinical signs due to B. hyodysenter-
iae infection in pigs under more challenging field condi-
tions. For this purpose, the effect on excretion of B.
hyodysenteriae was evaluated during and after a 6-day
treatment period in two wean-to-slaughter units in the
Netherlands.
Materials and methods
Inclusion of farms and animals
Two farms with clinical disease due to B. hyodysenter-
iae in grow/finisher pigs within two weeks preceding
the start of the study or preventing clinical signs due
to B. hyodysenteriae by strategic application of anti-
microbial drugs (but showing relapse upon cessation
of therapy) were included in this study. The clinical
signs of swine dysentery in Farm 1 were mainly char-
acterized by chronic diarrhea without very little pres-
ence of additions (mucus, necrotic material),
occurrence of runt pigs and increased mortality. In
Farm 2, the clinical signs of swine dysentery were
more pronounced with bloody diarrhea, addition of
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mucus and necrotic material combined with retarded
growth and finally mortality.
Pigs were not allowed to receive any preventive or
curative antimicrobial drug for B. hyodysenteriae in the
10 days preceding Study Day (SD) 0 (first day of admin-
istration of ID). Farms were representative for Dutch
commercial farms housing grow/finisher pigs under the
highest welfare conditions (three stars within the welfare
concept) with the possibility to realize administration of
ID via drinking water using a dosing pump. Animals
were fed dry feed and no increased levels of zinc or cop-
per via the feed or drinking water were allowed. Pens in-
cluded in the study had identical stocking density per
pen, feed, climate and management.
A pen was included when at least 10% of the animals
in the pen were qPCR-positive for B. hyodysenteriae at
SD − 3 and at least one of the pigs was showing a non-
normal fecal score (score 1 or higher on at least one
aspect as described below). Only post-weaned pigs,
showing non-normal fecal scoring and excreting B. hyo-
dysenteriae at SD − 3 and/or at SD0 or SD2 (the latest)
were included in the study for individual follow-up
within selected pens.
Administration of ID
Intra Dysovinol® 499 mg/ml (Elanco) consists of 499 mg
of Zn-Na2-EDTA per ml as an active ingredient in an
aqueous solution further containing colorants and a pre-
servative. Upon inclusion, the pen was randomly
assigned to control or treatment with ID at a dosage of
0.023 ml product per kg bodyweight for the duration of
6 days (according to SPC specifications), starting at SD0
and ending at SD6 (Table 1). Based on the total body-
weight and total water consumption of all animals in a
single pen, a 100 times concentrated pre-dilution was
dosed at 1% to the drinking water using a calibrated dos-
ing pump.
Clinical observations and fecal quality
All animal observations and collection of animal samples
were carried out by the observer. At pen level, general
health observations on all pigs in the selected pens were
recorded from SD − 3 until to SD14 (Table 1). Pigs were
individually identified by unique ear tag numbers. All in-
dividually identified pigs in a pen were weighed on SD0,
SD6 and SD14. Individual clinical observations were
conducted at SD 0, 1, 2, 3, 4, 5, 6, 10 and 14 and scoring
for general clinical condition, alertness, lameness and
signs of respiratory diseases. For evaluation of the fecal
quality, scoring was performed at SD 0, 2, 4, 6 and 14
according to the scoring grid in Table 2. Fecal scoring
included consistency, color and additions (mucus, foam,
blood and necrotic material) and was added to obtain
the total fecal score (TFS).
Real-time PCR and quantitative real-time PCR
Rectal fecal samples were collected at SD -3, 0, 2, 4,
6 and 14 in 50 ml sterile vials (MLS nv, Menen,
Belgium). At SD − 3, the samples were analysed for
the presence of B. hyodysenteriae by Real-Time PCR
based on the nox gene. At all other sampling time
points, the same real-time PCR was used combined
with a standard curve in order to obtain a quantita-
tive result (= quantitative real-time PCR). The cut-
off Ct value is 37. For PCR analysis, DNA was
extracted from 1 g of each individual faeces sample.
Extraction was performed with the MagAttract 96
Cador Pathogen Kit (Indical Bioscience, Leipzig,
Germany) according to the manufacturer’s instruc-
tions. Per g feces, 5 ml physiological solution was
added to the sample, after which the mixture was
thoroughly vortexed and 400 μl of supernatant was
collected for extraction. The real-time PCR was per-
formed using the BactoReal Kit B. hyodysenteriae
(Ingenetix, Vienna, Austria), which was based on the
Table 1 Study outline indicating the actions performed on the
different study days. I, individual level; P, pen level
Study day
Parameter Level -3 0 1 2 3 4 5 6 10 14
General health
observations
P X X X X X X X X X X
Treatment P X X X X X X X
Clinical observations I X X X X X X X X X
Faecal quality I X X X X X
qPCR faeces I X X X X X
Weighing I X X X
Table 2 Fecal quality scoring grid for assessment of individual
fecal quality. Sum (total fecal score, TFS) of fecal characteristics
A, B and C was used for statistical analysis
Parameters Score Description
A. Faecal shape and consistency 1 Hard, dry, can be shaped
by fingers
2 Normal, soft, but not
watery
3 Pasty, soft
4 Watery
B. Faecal color 0 Normal dark green, brown,
feed color
1 Light brown to yellow
2 Grey
3 Dark brown to black
C. Faecal additions 0 Normal, no additions
1 Slimy or foamy
2 Bloody or fibrinous exudate
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nox gene of B. hyodysenteriae, using the ABI7500 de-
tection system (Thermofisher, Massachusetts, USA)
with the following cycling conditions: 2 min incuba-
tion at 50 °C and 20s incubation at 95 °C comprise
the denaturation step, followed by 45 cycles of 95 °C
for 15 s and 60 °C for 1 min. The fluorescence data
were collected during the 60 °C – 1 min stage. The
real-time PCR was based on TaqMan technology. A
duplex PCR was performed using a probe labeled
with the FAM™ dye for the target gene and a probe
labeled with the Cy5® 186 dye for the internal posi-
tive control (IPC). This IPC was used to check for
PCR inhibition. PCR detection limit was 18 copies of
nucleic acid (i.e. 1.26 log10 cfu/g feces) per PCR
reaction.
For quantification, the quantitative real-time PCR
(qPCR) standard B. hyodysenteriae (Ingenetix, Vienna,
Austria), containing 107 copies/μl was used. Standard
curves were performed using four dilution points: 106–
105 – 104 – 103. Efficiency was between 85 and 115%
and R2 was at least 0.99. Based on these standard curves,
Ct values were translated into log10 cfu/gram feces (cfu =
colony forming unit).
Concomitant therapeutic treatment and unexpected
death
If a pig enrolled in the study developed an abnormal
health condition – such as profuse diarrhea, coughing
or lameness – an individual therapeutic treatment
was determined. In case an animal died or had to be
euthanized because of severe illness/welfare reasons
before SD0, the animal was disposed through regular
channels without further investigation. In case of
death/euthanasia after the treatment with ID or pla-
cebo had started, a fecal sample was collected for
qPCR analysis (either immediately before euthanasia
or as soon as possible after the pig was found dead)
and examined post-mortem or disposed through regu-
lar channels.
Justification of sample size
Sample size calculations for a two-sided two-sample t-
test were carried out in JMP 14.1 using the following pa-
rameters based on a previous field study with ID in the
Netherlands [22]:
 Observed standard deviation of 2 log10 cfu/g feces
between both groups
 Calculations were performed using following
statistical parameters:
 Alpha 0.05
 Power 95%
 Minimal difference to be detected of 2 log10 cfu/g
feces of B. hyodysenteriae
Based on these calculations, 60 pigs per treatment
group was sufficient and therefore, 120 animals were en-
rolled in the entire study, equally distributed over 2
farms.
Statistical analysis
The effect of treatment is tested for each time separately.
To account for the variability between farms, the binary
outcomes were analysed with a logistic regression model
with treatment and farm as factors. The other outcomes
were analysed with a linear regression model, again with
treatment and farm as factors. All model parameters
were estimated with the maximum likelihood method
and the hypothesis tests were performed as Wald tests,
which are for the linear regression model equivalent to
the least squares method and t-test, respectively. The P-
values (one for each time) were adjusted with the Bon-
ferroni method so as to control the familywise error rate
(FWER). All tests were performed at the nominal FWER
level of 5%.
Results
Farms and animals
In total 122 pigs in 2 farms and 9 pens have been en-
rolled in the study for close, individual follow-up. Five of
the initially selected pigs did not meet the inclusion cri-
teria as they showed no excretion of B. hyodysenteriae at
SD0. Therefore, data from 117 study pigs have been
used to assess the efficacy of ID in the treatment of clin-
ical signs due to B. hyodysenteriae infection under field
conditions in the Netherlands. Of the 117 enrolled pigs,
60 received ID treatment (2 pens on farm A, 2 pens on
farm B) and 57 received no treatment and were consid-
ered control (3 pens on farm A, 2 pens on farm B). On
farm A, the individually followed pigs had an average
bodyweight of 37.7 kg (range: 24.1–54.9 kg) on inclusion,
while the pigs on farm B were younger with an average
bodyweight of 15.2 kg (range: 9.4–22.4 kg). Bodyweights,
distribution of sex (female/male), level of B. hyodysenter-
iae excretion and fecal quality score did not differ sig-
nificantly at SD0 between ID-treated and control pigs as
evaluated by the median test (P > 0.05) and the propor-
tion test (P > 0.05), respectively.
Clinical observations and fecal quality
The general clinical score of the individually monitored
pigs was comparable between ID-treated pigs and con-
trol pigs at SD0, with 25 animals in both group scoring
normal (score 0). Following ID treatment, a rapid in-
crease in the percentage of animals with a normal gen-
eral clinical score occurred with 90% (54/60) of the
animals scoring normal at SD6 (Fig. 1). In the control
pigs, this general clinical score improved more slowly
over time, resulting in 73.6% (42/57) of animals scoring
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normal at SD6. Following the end of ID treatment, the
percentage of ID-treated pigs with a normal general clin-
ical score remained relatively stable (~ 86.7%), while the
percentage of control pigs with a normal general clinical
score decreased significantly at SD14 (P < 0.05). The per-
centage of pigs with a normal general clinical score was
significantly different (P < 0.05) between both groups
from SD4 until SD14.
The total fecal score (TFS) of the individually moni-
tored pigs was comparable between ID-treated pigs and
control pigs on SD0 with an average score of 3.16 and
ranging from 0 to 7 for both treatment groups (t-test,
P > 0.05). At SD0, TFS was numerically high in ID-
treated pigs, however, from SD2 to SD6, ID-treated pigs
had a lower TFS as compared to the control pigs (P >
0.05; Fig. 2). At SD14, 8 days after the end of the ID
Fig. 1 Percentage of ID-treated (n = 60) and control (n = 57) pigs with a normal general clinical score per study day from SD 0 to 14. Pigs were
treated with ID from SD 0 to 6. Significant differences (P < 0.05) are indicated with asterix*
Fig. 2 Total fecal score (average ± SEM) of ID-treated and control pigs per study day from SD 0 to 14. Pigs were treated with ID from SD 0 to 6.
Significant differences (P < 0.05) are indicated with asterix*
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treatment, TFS in ID-treated animals (TFS 0.39)
remained significantly lower (P < 0.01) as compared to
control pigs (TFS 1.23), which was mainly due to differ-
ences in the scores of fecal consistency and fecal color.
Overall, the ID-treated pigs showed an average daily im-
provement of their TFS by 0.74, whereas TFS in control
pigs only had an average daily improvement of 0.38.
Moreover, an increase in TFS was observed in control
pigs at SD14. Overall, at SD6, 25 of the 60 ID-treated
pigs showed a TFS of zero compared with 20 out of the
57 control pigs. At SD14, the number of ID-treated pigs
with a TFS of zero increased to 39 out of 60, while in
control pigs, this number remained at 20.
Real-time semi-quantitative PCR
Brachyspira hyodysenteriae nucleic acid was present at
comparable levels in both treatment groups (6.68 log10 vs.
6.28 log10 cfu/g feces for ID-treated and control pigs, re-
spectively) in all fecal samples collected at SD0, as deter-
mined by qPCR (t-test; P > 0.05, Fig. 3). At SD0, 2 out of 60
ID-treated pigs were B. hyodysenteriae-negative, while none
of 57 control pigs were PCR-negative for the pathogen
(Fig. 4). The number of B. hyodysenteriae-negative pigs in
the ID-treated group remained equal to the control group
at SD2, but increased to a maximum of 40 out of 60 at
SD4. A slight fall-back in the number of PCR-negative ID-
treated pigs (35/60) occurred at SD6, although their bacter-
ial load (expressed as log10 cfu/g feces) decreased to 2.21 at
SD6. Univariable analysis showed that B. hyodysenteriae
nucleic acid excretion was significantly reduced in ID-
treated pigs from SD4 to SD14 as compared to control pigs
(t-test, P < 0.05). Multivariable analysis showed that the
overall log10 cfu/g feces decreased significantly in ID-
treated pigs from SD0 to SD6 compared to control pigs:
ID-treated pigs showed a 4.48 log10 cfu/g feces reduction
from SD0 to SD6, whereas control pigs only had a 0.63
log10 cfu/g feces reduction over the same period (P < 0.05).
Average daily weight gain
The ID-treated pigs that were individually monitored
had a significantly higher ADWG (ADWG, g/day)
throughout the entire study as compared to the control
pigs (Fig. 5). During the treatment period (SD0–6),
ADWG in ID-treated pigs was at 825 g/day (± 61 g/d;
SEM), while control pigs grew only 619 g/d (± 63 g/d;
SEM). In the period following the end of ID treatment
(SD6–14), ID-treated pigs increased to an ADWG of
903 g/d ((± 57 g/d; SEM), whereas ADWG in control
pigs decreased to 505 g/day (± 59 g/d; SEM).
Concomitant therapeutic treatment, unexpected death
and adverse events
Due to persisting severe clinical symptoms of B. hyody-
senteriae infection in 20 control pigs (35%), it was neces-
sary to perform additional treatment with a single (n =
17) injection of tiamulin (Denagard 10%; Elanco) during
the study. Three pigs needed more than one injection,
namely two pigs were injected 3 times and one pig
needed in total 4 injections of tiamulin. The ID-treated
pigs did not require any additional treatment throughout
the entire study and no mortality was observed in both
treatment groups between SD0 and SD14. No adverse
Fig. 3 Log10 cfu B. hyodysenteriae per g of feces (average ± SEM) of ID-treated and control pigs per study day from SD 0 to 14. Pigs were treated
with ID from SD 0 to 6. Significant differences (P < 0.05) are indicated with asterix*
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events related to ID treatment were observed during and
after the study.
Discussion
The current study demonstrated that treatment with
zinc chelate (Intra Dysovinol® 499 mg/ml; ID, Elanco)
significantly reduced general clinical signs at SD3 and
SD14, while shedding of B. hyodysenteriae was reduced
with 4.48 log10 cfu per g feces during the treatment
period, resulting in 58.3% B. hyodysenteriae negative ani-
mals on SD6. Treatment with ID for 6 consecutive days
significantly improved TFS, which is an additive score of
fecal consistency, color and eventual additions (mucus,
foam, blood and necrotic material). The fecal quality
remained good after the end of the 6-day ID treatment,
although at SD14 an increase in B. hyodysenteriae-
Fig. 4 Percentage of B. hyodysenteriae PCR-negative ID-treated and control pigs per study day from SD 0 to 14. Pigs were treated with ID from
SD 0 to 6. Significant differences (P < 0.05) are indicated with asterix*
Fig. 5 Daily weight gain (average ± SEM) of ID-treated and control pigs per study period. SD0–6, ID treatment; SD6–14, follow-up with ID
treatment; SD0–14, entire study period. Significant differences (P < 0.05) are indicated with asterix*
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positive ID-treated pigs could be observed. This observa-
tion might be associated with the challenging housing
circumstances of the pigs in the current study. In con-
trast to Lammers et al. (2019) [22], who performed his
trials under conventional Dutch housing conditions, the
pigs in our trial were housed in a concept including a
high-welfare environment, which implicates more than
80% solid flooring, partly (50%) bedded with straw, and
only a very little slatted surface. These circumstances do
not favour the evacuation of B. hyodysenteriae-infected
feces throughout the study and might expose the pigs to
moderate to high amounts of potentially contagious fecal
material. Moreover, a high percentage of pigs consumed
liquid fecal material present on the solid pen floors.
In the current study, B. hyodysenteriae excretion did
not completely disappear at SD6 in contrast to the re-
sults reported by Lammers et al. (2019) [22]. Besides the
above mentioned factors related to differences in hous-
ing and environmental infection pressure, basic differ-
ences in sampling approach and subsequent qPCR
analysis were present. First, the fecal samples in the
current study were collected as a rather large volume of
feces in a sterile vial, which allows the analytic labora-
tory to weigh 1 g of feces from each vial for DNA extrac-
tion and subsequent qPCR analysis. In contract, E-swabs
were used by Lammers et al. (2019) [22], which impli-
cates that potentially less than 1 g of fecal material was
available for extraction. This difference in sampling ap-
proach might already influence the diagnostic sensitivity
of the qPCR. Secondly, the PCR cut-off Ct value of 40
corresponded with a limit of detection and limit of
quantification of 2.90 log10 cfu/g feces in the study by
Lammers et al. (2019) [22], whereas in our study, the
cut-off Ct value of 40 corresponded to 1.26 log10 cfu/g
feces. Taken together, these differences in sampling and
analysis might at least partially explain the observed dif-
ference in percentage of B. hyodysenteriae-negative ani-
mals between both studies at SD6.
The severity of the B. hyodysenteriae infection in both
farms required additional veterinary intervention in the
untreated control pigs. Before the start of the study,
antimicrobial sensitivity to tiamulin was checked for the
B. hyodysenteriae strains isolated and tiamulin MIC was
at 0.25 μg/ml in both farms. Overall, 35% of the control
pigs was administered one or more additional thera-
peutic treatments, whereas none of the ID-treated pigs
required additional therapeutic intervention.
Although bodyweight of the animals at SD0 was differ-
ent between farm A and B, no farm effect is expected on
the results, since both treatments were equally distrib-
uted between both farms, resulting in similar body-
weights for both treatment groups. The fecal quality
improved from 2 days after treatment onwards and con-
tinued TFS improvement was observed until 8 days after
the end of ID treatment. This rapid improvement in
clinical signs after ID treatment was in line with the
100-fold reduction in B. hyodysenteriae shedding within
2 days of ID treatment to an almost 10,000-fold reduc-
tion at 4 days in treatment. Although fecal scores contin-
ued to improved at SD6 and SD14, the qPCR results
indicated a slight increase in B. hyodysenteriae shedding,
which might be explained by the high environmental in-
fection pressure due to the specific housing conditions.
Considering the limit of detection by Lammers et al.
(2019) [22], which was at 2.90 log10 cfu/g feces, our
current qPCR results could also be considered ‘negative’
for B. hyodysenteriae shedding at the cut-off level of Ct
value 40. Therefore, based on the clinical signs and fecal
quality, we can conclude that the zinc chelate product
had a sufficient efficacy in the treatment of swine dysen-
tery due to B. hyodysenteriae.
The ability of B. hyodysenteriae to colonise the large
intestine and its specific virulence factors are still not
fully elucidated [2]. However, hemolysins, flagella,
lipooligosaccharides and bacterial chemotaxis have
been highlighted within the pathogenesis of swine
dysentery, besides specific virulence life-style factors,
such as outer membrane proteins, NADH oxidase and
proteins of iron metabolism [1]. It requires further in-
vestigation which mechanism causes the novel zinc
chelate to apparently prevent colonization and subse-
quently enhance the elimination of the pathogen [22].
In a mouse model for swine dysentery, the effect of
zinc methionine, ZnO and ZnSO4 has been assessed
and only ZnO levels of at least 2000 ppm demon-
strated a prophylactic effect against B. hyodysenteriae,
which is a considerably higher dose than what was re-
quired for the zinc chelate in the current study [20].
Another study reported no therapeutic effect of 250
ppm zinc chelate in the drinking water for 17 days to
pigs inoculated with B. hyodysenteriae, which may be
due to the nature of the chelating agent used [23].
Besides its impact on animal health and welfare, swine
dysentery due to B. hyodysenteriae has a tremendous im-
pact on the economic impact of an affected farm due to
reduced pig performance, increased antimicrobial treat-
ment costs and mortality. Annual losses of about € 133
per sow were calculated for fattening pigs affected by clin-
ical swine dysentery [24]. In the current study, growth re-
sults of the control pigs were significantly affected by
swine dysentery, although we could not observe weight
losses, in contrast to the study by Lammers et al. (2019)
[22]. The ID treatment had a significant positive impact
on pig performances with an overall ADWG of 869 g/d
from SD0 to SD14, while in the control pigs, the ADWG
was only 553 g/d. These results indicate that the intestinal
recovery at the level of the colon following ID treatment
had a continued effect for at least 8 days after the end of
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ID treatment, which was clinically confirmed by the stable
fecal quality and overall healthier appearance of the pigs
in the ID-treated group.
Water medication is a convenient and flexible route of
administration, permitting the farmer to apply the neces-
sary treatment to a specific category of animals, resulting
in an overall reduced use of therapeutics at farm level.
Moreover, during a disease outbreak, water consumption
remains stable for a much longer period as compared to
feed intake, which implicates that disease animals can
more efficiently be treated through this route of admin-
istration. During the trial, daily monitored water intake
indicated that sick pigs continued to drink, while feed
intake might be affected during the acute phase of B.
hyodysenteriae infection [3].
Conclusions
Intra Dysovinol® 499 mg/ml – containing a Zn-Na2-
EDTA complex – is a non-antibiotic treatment for swine
dysentery due to B. hyodysenteriae that reduces B. hyo-
dysenteriae shedding with 4.48 log10 cfu per g feces
within its 6-day treatment. Treatment improved general
clinical signs (90.0 vs. 73.6% animals with normal score
in ID-treated vs. control) at SD6 and TFS (0.39 vs. 1.23
in ID-treated vs. control) at SD14 in naturally B. hyody-
senteriae infected pigs. The positive effects of ID treat-
ment remain for at least 8 days after cessation of oral ID
therapy. Pigs remaining in a highly contaminated envir-
onment may be re-infected following the end of ID
treatment, however, this is not different to standard anti-
microbial therapy. Therefore, control of swine dysentery
should combine an efficacious treatment with additional
management practices to reduce the environmental in-
fection pressure in order to limit re-infection as much as
possible. The ID treatment resulted in a higher growth
rate and improved general health, whereas no mortality
was observed and no additional therapeutic treatments
were necessary in contrast to the control pigs.
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